Table 1.
Patient characteristics of the cohort
| All | MS and AID | MS without AID | MS without AID but ABF | MS without AID and without ABF | ||
|---|---|---|---|---|---|---|
| N (%) | 315 (100) | 43/315 (13.7) | 272/315 (86.3) | 64/272 (23.5) | 208/272 (76.5) | |
| Age (years), median (IQR 25%-IQR 75%) | 33 (26–42) | 34 (26–44.25) | 32.5 (26–42) | 33 (26–41) | 32 (26–42) | |
| Sex: female, n (%) | 208/315 (66) | 30/43 (69.8) | 178/272 (65.4) | 49/64 (76.6) | 129/208 (62) | |
| EDSS, median (IQR 25%-IQR 75%) | 2 (1.5–2.5) | 2.25 (1.625–3) | 2 (1.5–2.5) | 2 (1–3) | 2 (1.5–2.5) | |
| Clinical manifestation form n (%) | 1 | 119 (37.8) | 18 (41.9) | 101 (37.1) | 19 (29.7) | 82 (39.4) |
| 2 | 8 (2.5) | 0 (0) | 8 (2.9) | 2 (3.1) | 6 (2.9) | |
| 3 | 29 (9.2) | 7 (16.3) | 22 (8.1) | 2 (3.1) | 20 (9.6) | |
| 4 | 52 (16.5) | 4 (9.3) | 48 (17.7) | 11 (17.2) | 37 (17.8) | |
| 5 | 31 (9.8) | 3 (7) | 28 (10.3) | 8 (12.5) | 20 (9.6) | |
| 6 | 43 (13.7) | 6 (13.9) | 37 (13.6) | 15 (23.4) | 22 (10.6) | |
| 7 | 28 (8.9) | 5 (11.6) | 23 (8.5) | 4 (6.3) | 19 (9.1) | |
| 8 | 5 (1.6) | 0 (0) | 5 (1.8) | 3 (4.7) | 2 (1) | |
Clinical manifestation forms were categorized as following: 1: optic neuritis, 2: cortical manifestation with paresis, 3: cortical manifestation with exclusively sensory symptoms, 4: infratentorial symptoms, 5: spinal manifestation with paresis, 6: spinal manifestation with exclusively sensory symptoms, 7: polysymptomatic and 8: patients with no current symptomatic.
IQR, interquartile range; MS, multiple sclerosis; AID, autoimmune disease; ABF, isolated antibody finding; EDSS, expanded disability status scale